(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Fertiliser costs mean I'm better off not planting' - 2Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- 3Iran war drives global fertilizer prices up, raising food cost fears
- 4Don't miss the waxing moon swing by the Beehive star cluster March 27
- 5Norovirus is spreading earlier again this year, wastewater data shows
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- Novo and Lilly cut prices of weight-loss drugs in China
- Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
- 2025 among world's three hottest years on record, WMO says
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- The Meaning of Breaking the Pen's Nib in Death penalties
- Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life
- Factbox-Artemis II crew includes first woman, Black astronaut and Canadian ever flown to moon
- The Main 10 Natural life Protection Associations
